Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of pandemic H1N1 influenza vaccine formulations in healthy children aged 6 to 35 months
2009-013858-32Phase 2Completed
- Sponsor
- Sanofi
- Start
- Jul 2009
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2 trial of influenza A (H1N1) vaccine, A/California/7/2009 (H1N1) inactivated split virion influenza vaccine and trivalent influenza vaccine in influenza A virus infection (H1N1) (3 arms), sponsored by Sanofi. Primary endpoints: Immunogenicity by hemagglutination inhibition, Immunogenicity by seroneutralization and 1 more. Started Jul 2009; status: completed.
02
Drugs
influenza A (H1N1) vaccineA/California/7/2009 (H1N1) inactivated split virion influenza vaccinetrivalent influenza vaccine
03
Conditions
influenza A virus infection (H1N1)
Beyond the preview
Go deeper on 2009-013858-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-013858-32.